- Dec 31, 2023
NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma
NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies RRMM Study Assessing Activity of Intravenous (IV)...
50
- Dec 7, 2022
NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...
1,146
- Dec 1, 2022
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...
141
- Dec 1, 2022
NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)
(SUCCESSOR-2) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib...
286
- Dec 1, 2022
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa (Formerly TAK-573)...
124
- Dec 30, 2021
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
IFM 2020-02 MInimal Residual Disease Adapted Strategy (MIDAS) Isa-KRd NCT04934475: Phase 3 - IFM 2020-02 -MInimal Residual Disease...
1,140